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Abstract 
Recently, there has been an increased focus on inhalation therapies in drug delivery 
research.  It has been proven that many medications and vaccines can be inhaled in particle form, 
which has certain advantages.  Respiratory diseases such as asthma and emphysema can be more 
directly treated by administering medications to the lungs.  Even for non-respiratory conditions, 
the large internal surface area of the lungs provides a very effective means for entering the 
bloodstream.   
Particle processing of pharmaceuticals is commonly done in batches with toxic organic 
solvents; a large portion of drug processing costs come from multiple solvent separation steps.  
Another problem with batch processes is that it is difficult to achieve consistent particle size and 
distribution.  To overcome these issues, many innovative particle engineering methods have been 
developed using supercritical fluids as the solvents or anti-solvents.  One such process, ASES 
(Aerosol Solvent Extraction System), has proven to yield particles of the ideal size to administer 
by inhalation (1-5 microns) and uniform distribution necessary for reliable dosage.  Also, a 
supercritical fluid such as CO2, which is gaseous at room temperature, completely separates upon 
returning to ambient conditions.  This process has great potential to increase yield, increase 
throughput, and decrease processing costs.  This purpose of this study is to find trends for 
development of mathematical models and to show potential for realistically scaling up for 
industrial production.   
Key processing variables include drug solution flow rate, antisolvent flow rate, 
temperature, and pressure.  Preliminary experiments explored the effects of these variables on 
particle morphology using Bovine Serum Albumin (BSA) as a less-expensive model system.  It 
was found that increasing the system pressure decreases the size of the primary particles, but 
increases agglomeration due to frequency of particle collisions.  Increasing the system 
temperature also decreases the particle size, which indicates the need for a balance between 
achieving high density and high viscosity in the antisolvent.  For this system, solution and 
antisolvent flow rates appear to have the most pronounced effect on the resulting particles.  This 
would indicate that turbulence and other mass transfer effects are the most important. Furthering 
studies with BSA on a larger scale will help to understand the effects of scale on the important 
processing variables.   
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1. Introduction 
1.1 Motivation 
a. Pulmonary Administration 
 For thousands of years, inhalation has been used as a means for treating lung conditions.  
As recently as the 1990s, nebulizer and aerosol technologies have made substantial progress 
for systemic therapeutic application1.  This can be largely attributed to the allure of developing 
new, non-invasive techniques for administering medications and vaccines.  The large internal 
surface area of the lungs allows for effective uptake into the bloodstream that rivals the speed 
of injection; this makes pulmonary administration the most promising of the currently 
examined non-invasive delivery modes, including nasal, oral, and dermal2.  In order to be 
inhaled, the drug must be in particulate form.  The nominal particle size is 1-5 microns, which 
is a narrow range for effective absorption through the interior of the lung.  Particles that are 
smaller tend to be exhaled before reaching the lung, and larger particles tend to become lodged 
in the natural mucous linings of the respiratory system3.  As is evident, a narrow particle size 
distribution is vital for accurate dosaging.   
b. Commercialization 
 Conventional particle production techniques are unsuitable for such fine powdered 
pharmaceuticals.  Mechanical methods such as grinding and milling have large size variability, 
and can potentially denature the drug.  Chemical techniques, such as recrystallization, require 
excessive solvent use4; along with solvent/evaporation techniques, the final product requires 
expensive separation steps, or possibly several days of drying5.  Spray drying may require 
temperatures that thermally denature biological materials.  In order to industrially produce 
pharmaceutical powders for inhalation, processes with gentler operating conditions, reduced 
solvent use, and more reliable particle distribution are required.     
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1.2 Supercritical Fluids (SCF) Processes 
a. SCFs 
 A supercritical fluid is a continuous fluid phase that exists above a substance’s critical 
temperature and pressure.  At the critical point, illustrated in Figure 1-1, the gaseous phase and 
liquid phase are no longer distinguishable, and the fluid exhibits intermediate properties.   
 
Figure 1-1. Carbon Dioxide Phase Diagram6 
A SCF has low gas-like viscosity and high liquid-like density; this enables high diffusion rates 
and solvent properties, respectively.  The density of a SCF also fluctuates significantly with 
temperature and pressure, as shown in Figure 1-2, which allows for varying the solvation 
power of the fluid7.  These characteristics have been utilized in the development of many 
supercritical fluid particle formation processes.  These processes circumvent many of the issues 
related to conventional particle formation methods.   
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 A particularly common SCF for processing pharmaceuticals is carbon dioxide (SC-CO2).  
The critical temperature is 31.1C, and for biological molecules, such as protein medications, 
low processing temperature is favorable for stability.   
 
Figure 1-2. Carbon Dioxide Density Diagram8 
In general, carbon dioxide is also non-toxic and does not require separation steps like an 
organic solvent; many pharmaceuticals are insoluble in SC-CO2, so the CO2 completely 
separates when the system is returned to ambient conditions.  Typically protein medications are 
readily soluble in water, so aqueous solutions are used.  The drawback is that CO2 and water 
are relatively immiscible, so an organic solvent or co-antisolvent must be used.  A few of the 
popular SCFs processes for making pharmaceutical particles, specifically with SC-CO2, are 
subsequently described.     
b. Rapid Expansion of Supercritical Solutions (RESS) 
 The RESS process is suitable for substances that are soluble in SC-CO2; in this way, it is 
similar to a conventional recrystallization technique, only with the advantage of utilizing 
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temperature and pressure as a means to achieve supersaturation.  Also, since SC-CO2 is used as 
a solvent, no organic solvents are required.  A schematic of the process is shown in Figure 1-3. 
 
 
 
 
 
Figure 1-3. RESS Process Schematic7 
The drug of interest is solubilized in SC-CO2 in an autoclave; the temperature and pressure are 
chosen to have the maximum solubility without the formation of a liquid phase.  This saturated 
solution is decompressed through a nozzle, such that the SC-CO2 expands very rapidly, 
decreasing in density and solvent ability.  Different types of nozzles can be used to change the 
morphology of the resulting particles7.  This process has been studied extensively and 
successfully, and it is the most physically understood process of the ones mentioned here.  
Many mathematical models have been proposed for different physically realizable situations, 
such as one-dimensional solvent expansion and free jet expansion9.  The disadvantages of this 
process include the large volumes of gas required due to the fact that even drugs soluble in SC-
CO2 are not soluble in large amounts.  Also, the rapid depressurization of the solution through 
the nozzle poses a risk of freezing, as well as particle accumulation.  The preheater used before 
the nozzle to reduce this freezing risk also has the potential of heating the solution to the 
crystallization density, which also is of concern.     
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c. Gas Antisolvent (GAS) Recrystallization 
 In the GAS process, SC-CO2 is used as an antisolvent; as previously mentioned, most 
pharmaceutical compounds are insoluble in CO2, so there are more powders that can be 
processed with this method.  The drug is first dissolved in an organic solvent that is miscible 
with SC-CO2 at the process temperature and pressure in a precipitation vessel.  SC-CO2 is then 
pumped into the bottom of the vessel, which dissolves into the solution.  Because of the 
insolubility of the drug in SC-CO2, particles precipitate from the expanding solution.  This 
process has high throughput.  A schematic of the GAS process is shown in Figure 1-4.     
 
Figure 1-4. GAS Process Schematic10 
One disadvantage of this process is that it operates as a batch.  It also uses a significant amount 
of organic solvent, which inevitably requires stripping of residual solvent from the product7.   
d. Aerosol Solvent Extraction System (ASES) 
 The ASES process also utilizes the insolubility of most pharmaceuticals in SC-CO2.  It is 
similar to the GAS process in that the drug is dissolved in a solvent partially miscible with SC-
CO2, such that particles precipitate upon mixing.  The difference is that the ASES process is a 
semi-continuous spray process.  By using a nozzle to create an aerosol of the drug solution 
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before contacting the SC-CO2 antisolvent, supersaturation occurs more rapidly and uniformly, 
producing smaller particles.  The drug solution is pumped in though the inner diameter of a 
coaxial nozzle, while the antisolvent is pumped in through the outer diameter; the two meet at 
the tip of the nozzle, inside the pressurized vessel.  The antisolvent expands the drug solution 
and particles precipitate.  A filter at the bottom of the vessel catches the particles; for this 
reason, particle washing and collection is a batch process.  A schematic of the ASES process is 
shown in Figure 1-5.   
 
 
 
 
 
 
 
Figure 1-5. ASES Process Schematic11 
The main disadvantage of this process is that the mechanism for particle formation is poorly 
understood.  Also, when using aqueous drug solutions (which are common for proteins and 
other medications) a solvent or co-antisolvent must be used to overcome the relative 
immiscibility of water and CO2. 
1.3 Research Objectives 
 The goal of this research is to explore the effects of temperature, pressure, and solution 
and antisolvent flow rate on Bovine Serum Albumin (BSA) particles created using the ASES 
process.  These investigations aid in the development of relationships between these processing 
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variables and the resulting particle size and morphology.  Using the ASES process on an 
industrial scale is reliant on the development of theoretical models to predict and explain the 
process; another goal of this project is to apply knowledge gained and apply it to larger scale 
experiments.  This ultimately lends to discussing heuristics for industrial scale-up. 
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2. Literature and Theoretical Review 
2.1 ASES Literature Review 
 Since its development in 198912, the ASES process has been used extensively for particle 
production and microencapsulation.  From explosives to pharmaceuticals, the superior properties 
of supercritical fluids have allowed for smaller, more uniform particles.  Supercritical fluids have 
diffusivities that can be up to two orders of magnitude higher then traditional liquid solvents13, 
while having similar densities.  In combination with the aerosolization and rapid mass transfer 
provided by the coaxial nozzle, supersaturation and phase separation occur on the order of 10-5 
seconds; particle diameters can be reached that are below the minimum possible with traditional 
liquid recrystallization or milling13.  Additionally, the ASES method can produce particles with a 
larger percentage of fine particle mass (FPM, <5 μm).  Steckel et al. compared budesonide 
particles made using the ASES process to ones made with the conventional jet-milling process; 
they were able to obtain 47.9% fine particle mass using the ASES process, as compared to 29.0% 
using jet-milling14.   
 Fine particle mass is especially important for pulmonary delivery.  Particles that are <5 
μm in diameter are more able to penetrate into the smaller airways, which are often the target of 
local treatment in the lungs15.  However, particles <0.5 μm are exhaled, so a narrow size 
distribution is required for efficient delivery16.  Kim, et al. investigated the effects of flow rates 
and solvent type on the particle size and size distribution of poly(L-lactic acid) (PLLA) nano- 
and microparticles.  Spherical particles were produced using 1-4 dioxane (5-10 μm), 
tetrahydrfuran (THF) (0.5-1.0 μm), and dichloromethane (DCM) (0.2-0.8 μm)17.  A very 
comprehensive review of many of the polymers and pharmaceutical compounds micronised 
using the ASES process was written by Jennifer Jung and Michel Perrut10.  As an example, 
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amoxicillin was precipitated from N-methylpyrollidone (NMP) by Reverchon with a particle size 
range of 0.2-0.8 μm18.  As is evident, the ASES process has successfully produced particles in 
the size range of effective pulmonary delivery with narrow size distributions. 
 One drawback to the ASES process is agglomeration.  With the high frequency of 
collisions in the precipitation chamber during the ASES process and the turbulence, this is not 
surprising.  Particles of insulin, albumin, lysozyme, and myoglobin have all shown to form 
aggregates of primary particles19.  A study by Bustami, et al. for micronizing the first 
recombinant protein approved for human therapy by inhalation, recombinant human 
deoxyribonuclease (rhDNase), had up to 88.7% aggregates20.  Particle agglomeration may not be 
entirely undesirable, however.  New inhaler designs, such as the Turbuhaler™, actually utilize 
agglomerated particles, which are more stable during storage15.  When the inhaler is used, the 
shear forces from the air stream within the device break up the aggregates and disperse the 
individual particles.  A method for reliably producing such agglomerates would still be required.            
 Aside from the morphological advantages over typical pharmaceutical processing, there 
are significant processing and health advantages of a SCF process such as ASES.  
Pharmaceutical processes for either recrystallizing drugs from solutions or isolating them from 
solid matrices primarily use large amounts of organic solvents4.  Both waste streams containing 
organic solvents and trace amounts left in the final product are health concerns.  Not only does 
the ASES process use small amounts of cosolvents, but low residual content can easily be 
achieved in addition to easy separation of the organic solvent from the effluent stream21.  
Ruchatz et al. were able to reduce residual methylene chloride content in polylactic acid particles 
to 100 ppm using a SCF washing step that proved to significantly decrease the amount of time 
required compared to conventional drying techniques22.  Five different steroids, including the 
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common inhalant medication fluticasone, were successfully micronised using DCM as the 
solvent; the residual solvent content was <250 ppm and as low as 18 ppm23.  Using large 
amounts of organic solvents is also a concern because some proteins will denature with exposure 
to dimethylsulfoxide (DMSO), dimethylformamide (DMF), and others24.  Some cosolvents are 
less harmful to protein structure than others, such as ethanol25; in this study, lysozyme and 
trypsin were solubilized in a solution of water and ethanol.  The lysozyme particles retained 95% 
activity, while less than 40% of the trypsin bioactivity was maintained.  In a study by Winters et 
al., the stability and storage of proteins processed with ASES was investigated.  Insulin, trypsin, 
and lysozyme were processed using DMSO as the solvent, which resulted in minimal to 
intermediate alteration in secondary structure.  However, this did not affect the stability during 
storage as compared to conventionally lyophilized particles, and they were reconstituted 
successfully to native structure in aqueous solution26. It is evident that a specific protein requires 
individual consideration in choosing a cosolvent or coantisolvent. 
 Based on the results of a number of studies of the effects of processing variables on the 
resulting particle size and morphology, many aspects of the ASES process have different effects 
depending on the material being processed.  In the case of hydrocortisone acetate precipitated 
from DMF, lower temperatures resulted in smaller particles and pressure had little effect on the 
properties of the product27.  The previously mentioned study involving the micronisation of 
budesonide from DCM showed little variation in particle size or morphology when varying the 
CO2 and solution flow rates over a limited range14.  There was, however, a substantial effect on 
the aerodynamic properties of the particles obtained.  The also previously mentioned 
investigation of the precipitation of rhDNase from aqueous solution showed that varying the 
processing temperature over 20-45ºC resulted in little change in particle size.  However, there 
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was a substantial reduction in biological activity at temperatures above 35ºC20.  Other systems 
have shown substantial morphological and size effects when varying temperature and pressure.  
Thies and Muller found that increased pressure, which translates into increased antisolvent 
density from 0.25 to 0.69 g/mL, dramatically decreased particle size of PLLA precipitated from 
DCM from 50 to 6 μm28.  However, Randolph, et al. found that for the same system, increasing 
the density from 0.75 to 0.96 g/mL increased the particle size from 0.61 to 1.4 μm (referred to 
again later)29.  These discrepancies allude to the fact that the complicated mechanisms involved 
in the ASES process are not well understood, and appear to vary with processing conditions and 
processing material.  With this in mind, the two general theories applied to the ASES process 
will be explained subsequently.     
2.2 Theoretical Models 
a. Hydrodynamic Theory 
 The mechanism of particle formation in hydrodynamic theory focuses primarily on the 
aerosolization of the drug solution provided for by the coaxial nozzle.  Discrete solution 
droplets are formed as the jet leaves the nozzle tip, from which particles nucleate on contact 
with the antisolvent.  In this mechanism, the droplet size has the most influence on the 
resulting particle size.  The size of the droplets formed is dependent on the relative external 
pressure forces due to the antisolvent and the surface tension holding the droplets in tact, as 
described by the Weber number5: 
    
σ
DUρN
2
A
We =      2.1 
where ρA is the antisolvent density, U is the relative velocity of the solution and antisolvent, D 
is the droplet diameter, and σ is the interfacial surface tension.  The greater the Weber number, 
the smaller the solution droplets (and resulting particles) will be.  Since the surface tension is 
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relatively low and the density relatively high for SCFs, the Weber number is significantly 
large.  Since the density of a SCF increases dramatically with increased pressure, this should 
result in smaller particles. 
 Within hydrodynamic theory, there are two different proposed mechanisms for the actual 
particle nucleation process.  First, there is the one droplet-one particle theory, which as the 
name states, one particle precipitates from each droplet.  Therefore, the particle size is directly 
dependent on the droplet size; pressure should have a dramatic effect on particle size.  A visual 
representation of this theory is shown in Figure 2-1. 
 
Figure 2-1. One Droplet-One Particle Theory 
On the other hand, there is also the idea that multiple particles precipitate from each droplet.  
Multiple nucleation sites form within each particle as the antisolvent more rapidly penetrates 
the solution droplets.  Therefore, increasing the mass transfer between the two phases would 
cause multiple smaller particles to form within each droplet; not only do small droplets result 
in small particles, but so do turbulent conditions, high diffusivity, etc.  A visual representation 
is shown in Figure 2-2. 
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 Figure 2-2. Multiple Particle Theory 
b. Crystallization Theory 
 The mechanism of crystallization theory focuses primarily on turbulent mixing of the 
solution and antisolvent.  In this case, the interfacial surface tension is assumed to be so small 
that the Weber number becomes infinitely large and discrete solution droplets do not form.  
Particle nucleation is then a result of supersaturation within the gaseous plume formed by the 
nozzle and is dependent on the mixture kinetics and mass transfer.   
 
Figure 2-3. Crystallization Theory 
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In this manner, it is similar to a traditional solvent recrystallization process, only the rates of 
mixing in the ASES process are much higher due to the high density and low viscosity.  
Therefore, nucleation is much more uniform and produces much smaller particles.  A visual 
representation is shown in Figure 2-3. 
 
c. Proposed Models 
 The mechanism of particle formation in the ASES process is really a complicated mix of 
hydrodynamic, thermodynamic, and mass transfer effects.  As stated by Foster et al., both of 
the previously described mechanisms are supported in the literature and the exact mechanism 
appears to be system dependent11.  A review by Reverchon describes a few of these in detail13.  
As one example, Chang and Rudolph neglect the solute-solvent and solute-antisolvent 
interactions and treat the process as a binary system.  The particle formation is explained based 
on expansion behavior predicted by the Peng-Robinson equation of state.  Good results were 
obtained only in some cases, one being the precipitation of acetaminophen from toluene30.  
Rantakyla et al. made a model starting with experimental results obtained for PLLA in DCM.  
The model considered diffusion of the antisolvent into the droplet, the evaporation of the 
solvent from the droplet, and the solid particle formation.  The solid particle formation was 
modeled with an equation developed by Tom and Debenedetti that described particle size 
distribution with time31.  This model assumed that one particle formed from each droplet.  A 
more recent model developed after the Reverchon review by Lengsfeld et al. included the 
Peng-Robinson binary phase equilibria, classic jet breakup theory, and transient surface 
tension32.  This model can only be applied to dilute solution systems where the solute does not 
interfere with the binary dynamics.  Importantly, the model determined that the particle 
nucleation in dilute systems results from mixing, and not from discrete droplet formation.  This 
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model has limited applicability, especially considering that other experiments have shown that 
smaller particles form from more concentrated solutions18.       
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3. Experimental 
3.1 Experimental Setup  
a. Apparatus 
A schematic of the setup can be seen in Figure 3-1.  The system can be used with any 
combination of drug solution, antisolvent, flow rates (often a molar ratio of 1:50 solution to 
antisolvent33), pressure, and temperature. The drug solution (A) is pumped by a High 
Performance Liquid Chromatography (HPLC) pump (B).  A syringe pump (C) full of pure 
carbon dioxide is used to initially pressurize system as well as for flushing the vessel after 
spraying the drug.  Another syringe pump (D) is used if the carbon dioxide used as the 
antisolvent has a modifier.  The solvent and antisolvent flow through the coaxial nozzle (E) 
before reaching the precipitation vessel (F).  The particles are caught in a filter (G) with a 0.5 
micron mesh.  The outflow is sent through a metering valve (H) used to maintain the 
antisolvent flow rate to a dewar (I) filled with ice to condense any solvent and un-precipitated 
material for recovery.  The entire process is run inside a constant temperature water bath (J). 
 
Figure 3-1. Experimental Apparatus 
A 
B C 
D E
F
G
H 
I 
J
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b. Coaxial Nozzle 
The defining characteristic of the ASES process is the use of a coaxial nozzle.  The inner 
nozzle is Polyethertetherketone (PEEK) tubing with a diameter of 50 microns and has the drug 
solution flowing through it.  This feature, in combination with the large pressure drop between 
the pumping source and the precipitation vessel, creates an aerosol spray.  The antisolvent then 
flows through the outer annular space of the nozzle between the PEEK tubing and the outer 
1/16” stainless steel tubing.  A side view and a cross-sectional view of the coaxial nozzle can 
be seen in Figure 3-2.  The spraying further aids the mixing of the antisolvent and drug 
solution upon contact in the precipitation vessel.  Super-saturation occurs due to the drug being 
insoluble in the antisolvent, and particles precipitate. 
 
CO2 CO2
D
rug Solution 
 
50 microns 1.59 mm 2.16 mm 3.18 mm 
 
Figure 3-2. Coaxial Nozzle 
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Mawson et al investigated the use of a coaxial nozzle as opposed to a standard nozzle.  Using the 
standard nozzle, solution droplets were evident throughout the vessel due to inadequate mixing 
with the antisolvent.  Although the standard nozzle achieved better aerosolization due to the 
larger relative velocity between the solution and antisolvent, the poor mixing resulted from 
insufficient turbulence outside of the jet.  Due to this, the particles dried more slowly and would 
become highly agglomerated.  Using a coaxial nozzle increases mass transfer between the two 
phases and causes better particle nucleation34.   
3.2 Procedure 
a. Antisolvent Preparation 
 Initially, pure SC-CO2 was used as the antisolvent, which would reinforce the non-toxic, 
benign nature of the process.  As was mentioned earlier, pure CO2 is relatively immiscible 
with water, which was the case with the aqueous protein solution.  Inside the pressure cell, 
condensation formed on the glass as the SC-CO2 antisolvent was unable to penetrate the drug 
solution spray.  A photograph of this behavior during an experiment is shown in Figure 3-3. 
Water droplets 
 
Figure 3-3. Immiscible Solution/Antisolvent 
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It was then evident that the system would require an organic solvent to increase the miscibility 
of the drug solution and the antisolvent.  To do this, ethanol was added as a co-antisolvent19.  
To prepare the modified antisolvent, the ethanol was added in an amount equivalent to 20 
mol% and the pump was cooled to add liquid CO2.  This mixture was cooled and heated 
several times to assure complete mixing within the syringe pump.  Using a modified 
antisolvent required consideration of the ternary behavior of the water-CO2-ethanol system to 
avoid phase splitting in the pressure vessel.  Additionally, the pressure vessel was initially 
pressurized using pure CO2 before adding the modified antisolvent to prevent phase splitting.   
b. Drug Solution Preparation 
 The protein of interest in these experiments was Bovine Serum Albumin (BSA), which is 
often used as an inexpensive model protein in experimentation.  As previously mentioned, the 
drug solution contained water as the solvent; BSA concentrations of 15-80 mg/mL were used.  
Even after employing the use of the modified antisolvent, the drug solution and antisolvent 
appeared to not be miscible enough for supersaturation.  Increasing the amount of ethanol in 
the antisolvent made them too miscible; that is, condensation formed similarly to when pure 
SC-CO2 was used.  As a solution, the amount of ethanol was decreased in the antisolvent and a 
small amount of ethanol was added to the drug solution.  However, when preparing the ternary 
drug solutions, gels would form.  Phase diagrams such as that shown in Figure 3-4 demonstrate 
the behavior of these solutions.  Region 1 would form a solution, while the others were gels or 
other forms of insoluble solids.  The low concentrations to make a solution were undesirable, 
so aqueous solutions were again used.  The solutions for the results comparison were 50 
mg/mL BSA in HPLC grade water. 
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Figure 3-4. Ternary Phase Diagram (BSA-Ethanol-Water)35  
c. Conducting the Experiment 
 The antisolvent is first prepared in a syringe pump to be cooled overnight and mixed in 
the hours preceding the experiment.  A few hours before, the bath temperature is set, the drug 
solution is prepared and placed in the refrigerator, the vessel is pressurized with pure CO2, and 
the antisolvent is heated to begin the mixing process.  The antisolvent is heated by circulating 
the water from the bath through the pump jacket, cooled with ice water, and then heated again.   
   To begin an experiment, the antisolvent syringe pump is run at constant pressure, using 
the metering valve to set the initial flow rate. Once the initial antisolvent flow rate is set, the 
HPLC pump is used to increase the pressure of the drug solution to about 2000 psi greater than 
the system pressure before opening the valve to the nozzle.  The drug solution is then sprayed 
in for approximately one minute to prevent the filter from clogging with particles.  When 
particles are precipitating, a white fog appears inside the vessel, as seen in Figure 3-5.   
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a. b. 
Figure 3-5. Particle Precipitation (a. Pressurized Vessel  b. Particle Fog) 
If this is not evident, or there are visible droplets of solution falling from the nozzle, the flow 
rates are readjusted.  If condensation forms, the solution valve is closed so that pure CO2 can 
flush out the excess water and ethanol before attempting to resume spraying.  After particles 
form, more antisolvent is flushed through, followed by the washing step.      
d. Particle Recovery and Analysis 
Following every run, the nozzle is back-flushed to remove any remaining liquid, and 
approximately 200 mL of pure carbon dioxide is used to wash any residual ethanol and water 
in the entire system.  The system is then de-pressurized, and the precipitation chamber 
removed from the water bath to recover particles.  Figure 3-6 shows an example of the filter, 
which fits snugly inside the large threaded fitting in the bottom of the vessel, removed from the 
vessel and covered in particles.  The powder is collected in glass vials after preparing samples 
for Scanning Electron Microscopy (SEM) and stored in the freezer. 
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 Figure 3-6. Filter with Particles 
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4. Results and Discussion 
 Due to the small amounts of powder recovered during successful runs and the often 
heavily agglomerated state of the particles, analysis was very qualitative.  Ideally, powders 
consisting of spherical particles would be produced for size distribution analysis.  In this case, 
SEM images were used as a basis for comparing and understanding the basic effects of pressure, 
temperature, and flow rate over small ranges.   
4.1 Pressure Effects 
 All experiments were conducted well above the critical pressure of CO2 (73.8 bar, 1070 
psi).  It was found that precipitation occurred for the system using the previously specified drug 
solution and antisolvent composition between 2000-2500 psi.  Images of particles made at the 
upper and lower limits of this pressure range and 45ºC can be seen in Figure 4-1. 
       
 
 
 
 
a.           b. 
Figure 4-1. Pressure Effects (a. 2000 psi  b. 2500 psi) 
It is evident that the primary particle size is much larger at 2000 psi than 2500 psi.  This is 
attributed to the fact that the increased system pressure increases the supercritical antisolvent 
density (see Figure 1-2); the antisolvent is more able to mix with and expand the drug solution.  
Obtaining smaller particles from larger pressures is consistent with both of the previously 
discussed theories; hydrodynamic theory would explain this as a result of greater jet-break up 
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from the increase in external pressure forces relative to the surface tension between the drug 
solution droplets and the antisolvent.  The cause of the agglomeration is a little less clear.  It 
could simply be an effect of the increased surface energy of the smaller particles, some effect 
related to the complicated solution behavior of BSA in the presence of water and ethanol, or it 
could be related to the drug solution concentration.  Many studies find that increasing the drug 
solution concentration (up to a certain threshold) increases the rate of particle nucleation, and 
subsequently decreases agglomeration19,36.  This possibility is not explored further 
experimentally here, but seems to be more consistent with crystallization theory.  The decreased 
particle size with increased pressure is also consistent with this theory; only in that case, the 
smaller primary particles are a result of the increased mass transfer between the solution and 
antisolvent due to the increased antisolvent density.  The increased supersaturation results in 
more sites of nucleation and therefore smaller resulting particles.  In general, it appears as though 
both the hydrodynamic theory and the crystallization theory dominate at different conditions in 
the same system.  This observation is supported by the work of others5, 8.      
4.2 Temperature Effects  
 The system temperature does not have much flexibility in the ASES process.  The 
temperature must be above the critical temperature of CO2 (31.1ºC), but also must remain within 
a range that will not accelerate protein denaturation.  Taking this into consideration, all 
experiments were conducted in the range of 35-45ºC.  Images of particles obtained at the upper 
and lower limits of this range and a pressure of 2000 psi are shown in Figure 4-2.  As is evident, 
the primary particle size decreases as temperature increases.  This is likely due to a combination 
of effects; the reduction in antisolvent viscosity (and increase in diffusivity) increases the mass 
transfer between the solution and antisolvent, and altering the mixture thermodynamics via 
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reduced solubility of the drug in the solution/antisolvent mixture and increased nucleation rates.  
From this and the previous effects of increased antisolvent density, the mass transfer (and 
therefore overall ability of the antisolvent to expand and supersaturate the drug solution) seems 
to be a balance of high density and high diffusivity.  This implies that there is an optimum 
temperature and pressure that, when exceeded, will cease to reduce the resulting particle size.       
 
 
 
 
  
a.          b.   
Figure 4-2. Temperature Effects (a. 35ºC  b. 45ºC) 
This is reflected in work by Randolph et al. that studied the effects of increasing the CO2 
antisolvent density29; increasing the density from 0.65 to 0.76 g/mL increased the resulting 
particle size.  This implies that the reduction in diffusivity has a more dominant effect than the 
increase in antisolvent density. 
4.3 Flow Rate Effects 
 Both the ratio of solution to antisolvent flow rate, as well as the overall magnitude of the 
flow rates, has an effect on the particle formation process.  For the solution and antisolvent 
compositions specified in these experiments, ratios of antisolvent:solution ranging from 40:1 to 
30:1 are effective.  In general, it is observed that increasing the overall flow rates while 
maintaining the same ratio does not necessarily result in particle formation.  This non-linearity is 
a factor when considering scale-up, and will be discussed further later.  Figure 4-3 shows images 
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obtained from two portions of the same powder sample collected from a single experiment using 
a solution flow rate of 1.0 mL/min and an antisolvent flow rate of 30 mL/min.  The experiments 
for investigating flow rate effects are at 40ºC and 2000 psi. 
     
 
 
 
 
a. b. 
ure 4-3. Particle Morphologies Observed (a. spherical  b. fibrous) 
Figure 4-3a -3b has the 
ticles; in 
the comparison.  Figure 4-4 is an SEM image of the resulting powder. 
Fig
 is an example of a spherical particle in the desired size range.  Figure 4
appearance of intertwined chains subject to high shearing effects, similar to that observed by 
Shekunov, et al. when using ASES to produce polymer microparticles.  This is attributed to 
denatured protein chains in the solution; denatured protein chains lose their folded conformation 
and can become linearized, similar to polymer chains.  This is not only an issue because of the 
loss of biological function, but also because this type of particle morphology could lead to filter 
clogging; the issue of denaturation will be addressed further when discussing scale-up. 
 According to theory, decreasing the flow rates should lead to larger par
hydrodynamic theory, this is because of lesser jet break up producing larger solution droplets, 
and due to decreased turbulence and mass transfer in crystallization theory.  As was previously 
mentioned, the flow rate ratio can not be maintained as the overall magnitude of the flow rates 
change, so the combination of 0.5 mL/min drug solution and 20 mL/min antisolvent is used in 
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Decreasing the overall ma  rates results in precipitation, but the 
supersaturation is insufficient articles.  This result is more 
 little known about the exact mechanism of 
n, nucleation, and crystal growth in the ASES process.  The proposed models only 
 
ariables.  This invariably indicates that the process itself is very complex 
Figure 4-4. Amorphous Particles 
gnitude of the flow
for obtaining discrete, spherical p
consistent with the crystallization theory, where insufficient mass transfer results in slow 
nucleation so crystals form instead of particles.  
4.4 Scale-up 
 As was previously mentioned, there is
supersaturatio
pertain to specific conditions for a few systems; many systems, such as the one described here, 
show characteristics that can be explained by both models.  Without a more comprehensive 
mathematical model, scale-up is very difficult.  A few of the more important issues concerning 
industrial scale-up and how they relate to the previously described experiments will be discussed.   
a. Considerations 
  The results described for this system indicate the sensitivity of the ASES process to 
many processing v
and can not be easily scaled proportionally.  The more obvious ways to increase the scale of 
this process would be to increase the flow rates, nozzle diameter, vessel size, or a combination 
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of these.  To increase the flow rate and process more material, the nozzle diameter must be 
increased to achieve the same pressure drop.  In doing this, the mixing dynamics change as the 
mass transfer must occur over a larger area; the dynamics of the system happen on such short 
time scales, that small changes can have a significant effect on the precipitation kinetics.  The 
spray dynamics may also change, because as the scale gets larger, it will be more difficult to 
achieve aerosolization.  Developing correlations that take all of these effects into account 
would be ideal, but that has yet to be accomplished.  A more feasible short-term option would 
be to conduct experiments on larger scale equipment to find empirical relationships; this will 
only apply to a particular system, but it is an option. 
 Another consideration is that the aqueous system described here contacts CO2, which can 
lower the pH.  At such high pressures, the pH can become as low as 3.037.  When dealing with 
SES process with aqueous protein 
proteins, pH changes can cause denaturation.  Aside from losing biological activity, 
precipitation may be induced by surface charge changes21.  
 In pharmaceutical processes, residual solvent content is always a consideration for 
product purity.  As stated previously, using SC-CO2 in the A
solutions requires the addition of a solvent; in this case, the antisolvent is modified with 
ethanol.  Although the lab scale system is washed with a large volume of pure CO2, there are 
instances where the particles redissolved upon depressurization because of residual solvent 
content.  So, not only for product purity, but for product recovery, an efficient washing step is 
absolutely required.  Effects such as cake resistance, filter pore size, miscibility of the solvent 
with CO2, the affinity of the solvent for the particles, and the amount of solvent present need to 
be considered.  Many studies have been done to investigate the amount of time required for 
effective washing22, 38, which is typically much shorter than the times required for conventional 
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drying techniques.  Ideally, the vessel should be designed to achieve a plug flow when washing 
instead of mixing; this would make a large narrow vessel more attractive.  Practically, this puts 
a limitation on height for stability, as well as the dynamics of particle/antisolvent interactions 
as they come into contact for longer times. 
 Particle recovery is an issue with the ASES process.  On the laboratory scale, the particle 
formation process is continuous, but the particle washing and recovery are done as a batch.  To 
ling-up, correlations are needed for 
increasing nozzle diameter, flow rates, solution concentration, etc.  It is very likely that all of 
th e v
collect particles, the entire system is depressurized and the vessel must be taken apart.  This 
would not be feasible on the industrial scale, because it is both labor and time intensive.  
Additionally, if particle recovery were made continuous in some way, there is still the issue of 
filter blockage, which would require system depressurization.  One positive consideration 
concerning particle recovery is that for many pharmaceutical processes, production capacity 
can be on the order of only a few kilograms per year.       
b. Design Options 
 To maintain the same spray dynamics when sca
es ariables are independent of each other with scale.  However, a more plausible method is to 
determine the most influential processing variables and the effect of scale.  As suggested by 
Thiering, et al, a process should be designed to achieve efficient mixing, such that the mixture 
kinetics is the limiting factor21.  In doing so, variables such as temperature and pressure that 
affect the diffusivity and miscibility would be controlling.  The simpler option for maintaining 
the same spray and mixing dynamics would be to use multiple identical nozzles in one large 
vessel.  In the event that wall effects and other controlling factors are altered by using a large 
vessel, multiple identical units could be used in parallel.   
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 To overcome the issues related to particle collection, multiple, independently pressurized 
particle collection units could be used.  That way, particle production in the vessel could be 
co tinun ous, and it would not need to be depressurized in order to collect particles.  This method 
is favorable, because if there are issues with clogged filters, the process will not need to be taken 
offline.  Another way to circumvent filter issues is to use other methods for particle collection.  
Traditional particle filtering methods such as cyclones could be used; issues with agglomeration 
would need to be investigated to use this type of separation.  In the case of the innate 
electrostatic character of proteins, an electrostatic precipitator could be used to pull the particles 
out of the effluent stream with electric fields.  The concern here would be possible reversible 
alteration in protein structure.  Theiring et al. also suggested the possible use of a cyclone with 
charged walls to combine the features of the two separation techniques21.     
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5. Conclusions and Recommendations 
 The Aerosol Solvent Extraction System (ASES) is a supercritical fluids process that is a 
viable option for the production of small particles for pulmonary drug delivery.  Using 
supercritical carbon dioxide (SC-CO2) as the antisolvent allows for low processing temperatures; 
this is especially important for biological molecules such as proteins.  Particles can be produced 
in the optimal range for lung deposition with narrow size distribution and high bioavailability.   
 To date, the ASES process is not well understood.  The work presented here supports 
theories applied in the literature to the ASES process, which shows promise for developing 
models.  Increasing the system pressure decreases the size of the primary particles, but increases 
agglomeration due to frequency of particle collisions.  Increasing the system temperature also 
decreases the particle size, which indicates the need for a balance between achieving high 
density and high viscosity in the antisolvent.  For this system, solution and antisolvent flow rates 
appear to have the most pronounced effect on the resulting particles.  This would indicate that 
turbulence and other mass transfer effects are the most important for this system of bovine serum 
albumin (BSA) and aqueous solution with ethanol-modified carbon dioxide antisolvent.   
For this process to be feasible on an industrial scale, mathematical models and 
correlations for predicting the effects of processing variables on particle size and morphology are 
necessary.  Applying the knowledge gained in this study to larger scale laboratory equipment 
will help to better understand the effects of scale on mixture thermodynamics, hydrodynamics, 
and mass transfer.  It is also important to extend the studies to other model proteins to find 
general trends having to do with protein size, shape, and surface charge.  The wide applicability, 
as well as the superior particle processing capabilities of the ASES process indicate that further 
work is necessary. 
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